草案中列出了提交許可申請(qǐng)時(shí)所需的信息和數(shù)據(jù)，涉及具體配方的安全性和適用性，以及配方對(duì)降低嬰兒乳蛋白過(guò)敏風(fēng)險(xiǎn)的效果。

 

    本次指南還需進(jìn)一步審議與更新完善。

 

    部分原文報(bào)道如下：
 

     EFSA has launched a public consultation on its draft guidance for the preparation and presentation of applications for authorisation of infant or follow-on formulae manufactured from protein hydrolysates.

 

    The guidance document specifies what kind of information and data applicants need to submit. It covers applications for the assessment of the safety and suitability of the specific formula and applications on the formula's efficacy in reducing the risk of infants becoming allergic to milk proteins.

 

    EFSA invites interested parties to submit written comments by 3 March 2017.

 

    原文鏈接：http://www.efsa.europa.eu/sites/default/files/consultation/170113a.pdf